CVRx, Inc.
CVRXNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $56.7M | $51.3M | $39.3M | $22.5M | $13.0M | $6.1M |
| Operating income | −$51.3M | −$59.5M | −$43.1M | −$42.5M | −$26.0M | −$11.5M |
| Net income | −$53.3M | −$60.0M | −$41.2M | −$41.4M | −$43.1M | −$14.1M |
| Total assets | $104.8M | $133.4M | $115.2M | $124.9M | $152.5M | $64.8M |
| Total liabilities | $65.5M | $62.4M | $39.3M | $15.8M | $6.6M | $28.0M |
| Equity | $39.3M | $71.1M | $75.9M | $109.2M | $146.0M | −$293.2M |
| EPS (diluted) | $-2.04 | $-2.65 | $-1.99 | $-2.02 | $-4.16 | — |
| Shares out. | 26.0M | 20.9M | 20.7M | 20.5M | 20.4M | 360,412 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −90.5%
- Net margin
- −94.1%
- Return on equity
- −135.6%
- Return on assets
- −50.9%
- Return on capital (ROCE)
- −56.0%
- Liabilities / assets
- 62.5%
- Debt / equity
- 1.66×
- Book value / share
- $1.51
- Revenue growth (YoY)
- 10.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -15.50distress
- Accruals / assets
- −12.5%clean
- Beneish M-Score
- -3.04normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Johnson & JohnsonPassive (13G)Jan 12, 2026
- New Enterprise Associates 10 L PActivist (13D)Feb 20, 2025
- Cooperatieve Gilde Healthcare Iv U.A.Activist (13D)Feb 6, 2025
- Vensana Capital I Gp, LlcPassive (13G)Feb 6, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Adamson Philip B.Officer — Chief Medical Officer | Feb 27, 2026 | Grant | 41,000 | $0.00 |
| Morrison GregoryOfficer — CHIEF HUMAN RESOURCES OFFICER | Mar 2, 2026 | Grant | 34,000 | $0.00 |
| Hykes KevinOfficer — PRES & CEO | Feb 27, 2026 | Grant | 159,000 | $0.00 |
| Verrastro PaulOfficer — CHIEF MKTG & STRAT OFFICER | Feb 27, 2026 | Grant | 45,000 | $0.00 |
| Oasheim JaredOfficer — CHIEF FINANCIAL OFFICER | Feb 27, 2026 | Grant | 61,000 | $0.00 |
| John Robert AllenOfficer — Chief Revenue Officer | Feb 27, 2026 | Grant | 35,000 | $0.00 |
| Binkowski BrentOfficer — CHIEF OPERATING OFFICER | Feb 27, 2026 | Grant | 15,000 | $0.00 |
| Jain Mudit K.Director | Feb 20, 2026 | Buy | 46,800 | $6.36 |
| Jain Mudit K.Director | Feb 18, 2026 | Buy | 600 | $4.64 |
| Johnson &Amp; Johnson10% owner | Nov 26, 2025 | Sell | 6,337 | $10.03 |
| Johnson &Amp; Johnson10% owner | Nov 21, 2025 | Sell | 500 | $10.00 |
| Johnson &Amp; Johnson10% owner | Nov 12, 2025 | Sell | 1,000 | $10.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.9M | 4.0 | +9.1% |
| Apr 30, 2026 | 1.7M | 6.5 | +4.7% |
| Apr 15, 2026 | 1.7M | 6.2 | -1.4% |
| Mar 31, 2026 | 1.7M | 7.8 | -5.3% |
| Mar 13, 2026 | 1.8M | 7.5 | -7.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 11, 2026
- Results of operations · Other material eventApr 13, 2026
- Director / officer changeMar 3, 2026
- Results of operationsFeb 12, 2026
- Entered a material agreementJan 12, 2026
- Entered a material agreement · Results of operations · New financial obligation · Other material eventJan 12, 2026
- Results of operationsNov 5, 2025
- Results of operations · Director / officer changeAug 4, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SDFORM SDMay 28, 2026
- 10-QMay 12, 2026
- 8-KFORM 8-KMay 11, 2026
- DEFA14AApr 20, 2026
- DEF 14AApr 20, 2026
- 8-KFORM 8-KApr 13, 2026
- 4Mar 16, 2026
- 4Mar 4, 2026
- 3Mar 4, 2026
- 4Mar 3, 2026
- 4Mar 3, 2026
- 4Mar 3, 2026
- 4Mar 3, 2026
- 4Mar 3, 2026
- 8-KFORM 8-KMar 3, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.